<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029896</url>
  </required_header>
  <id_info>
    <org_study_id>HBCP01</org_study_id>
    <nct_id>NCT04029896</nct_id>
  </id_info>
  <brief_title>Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy</brief_title>
  <official_title>Individual Patient Expanded Access IND of Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <brief_summary>
    <textblock>
      This is an Individual Patient Expanded Access Protocol of Autologous HB-adMSCs for the&#xD;
      Treatment of Cerebral Palsy (CP) with the primary goal of treating 1 individual with CP who&#xD;
      has exhausted all treatment options, his condition has not improved, his quality of life is&#xD;
      severely affected by the condition and he has previously banked his mesenchymal stem cells.&#xD;
      There are no FDA approved, fully restorative treatments for CP. The subject will receive 8&#xD;
      autologous HB-adMSC infusions of 50 million (50 x 10^6 cells) total cells. A protocol&#xD;
      amendment to administer additional HB-adMSC infusions may be submitted for IRB/FDA for&#xD;
      approval depending on the patient's response, AE/SAEs, and cell expansion characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline&#xD;
      visit, the subject will return for the first infusions. Subsequent treatments will occur&#xD;
      every other week.&#xD;
&#xD;
      On each of these visits, the subject will receive one autologous HB-adMSC infusion of 50&#xD;
      million (50 x 10^6 cells) total cells. Every infusion visit will include the following&#xD;
      procedures:&#xD;
&#xD;
        1. Interval H&amp;P update,&#xD;
&#xD;
        2. Weight&#xD;
&#xD;
        3. Vital signs monitoring (Heart Rate, BP, Resp., Temp., SpO2),&#xD;
&#xD;
        4. A urine and blood sample for clinical labs (CBC with diff., CMP, and Coagulation Panel,&#xD;
           Serum Leptin),&#xD;
&#xD;
        5. A verification of patient/LAR consent will be verbally performed,&#xD;
&#xD;
        6. The HB-adMSC infusion will be given via IV over a 1 hour period.&#xD;
&#xD;
        7. The subject will then be monitored for a minimum of 4hr.&#xD;
&#xD;
        8. 24-hour telephone assessment for adverse events&#xD;
&#xD;
        9. Video Documentation&#xD;
&#xD;
      Follow Up Visits Week 4, 8, 12 and 16 (Safety Assessments)&#xD;
&#xD;
      The patient will be assessed for adverse events 24 hours after each infusion with a follow up&#xD;
      phone call. 4 weeks after the first infusion have occurred, the subject will return to the&#xD;
      clinical site for an onsite safety assessment, which will be repeated at week 8, 12, and 16.&#xD;
      Each one of these on-site safety assessments will include:&#xD;
&#xD;
        1. Review and update medical history,&#xD;
&#xD;
        2. Update concomitant medications list&#xD;
&#xD;
        3. Video documentation&#xD;
&#xD;
        4. Weight&#xD;
&#xD;
        5. Vital signs (Heart Rate, BP, Respirations, Temp., SpO2),&#xD;
&#xD;
        6. Physical exam,&#xD;
&#xD;
        7. A urine and blood sample for clinical labs (CBC with diff., CMP, and Coagulation Panel&#xD;
           and serum leptin)&#xD;
&#xD;
        8. SARAH assessment on Weeks 4, 12 and 16.&#xD;
&#xD;
        9. Adverse event monitoring Follow Up Visit Week 26 (Safety Assessments)&#xD;
&#xD;
      1. Review and update medical history, 2. Update concomitant medications list 3. Weight 4.&#xD;
      Vital signs (Heart Rate, BP, Respirations, Temp., SpO2), 5. Physical exam, 6. A urine and&#xD;
      blood sample for clinical labs (CBC with diff., CMP, and Coagulation Panel and serum leptin),&#xD;
      7. Brain MRI 8. The SARAH (motor-functional evaluation scale for children and adolescents&#xD;
      with cerebral palsy) 9. Adverse event monitoring 10. Video documentation&#xD;
&#xD;
      Follow Up Visit Week 52 (Safety Assessments-End of Study)&#xD;
&#xD;
        1. Review and update medical history,&#xD;
&#xD;
        2. Update concomitant medications list&#xD;
&#xD;
        3. Weight&#xD;
&#xD;
        4. Vital signs (Heart Rate, BP, Respirations, Temp., SpO2),&#xD;
&#xD;
        5. Physical exam,&#xD;
&#xD;
        6. A urine and blood sample for clinical labs (CBC with diff., CMP, and Coagulation Panel&#xD;
           and serum leptin),&#xD;
&#xD;
        7. Chest X ray (PA Single view)&#xD;
&#xD;
        8. The SARAH (motor-functional evaluation scale for children and adolescents with cerebral&#xD;
           palsy)&#xD;
&#xD;
        9. Adverse event monitoring&#xD;
&#xD;
       10. Video documentation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Cerebral Palsy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSCs</intervention_name>
    <description>intravenous infusion of Hope Biosciences autologous adipose-derived stem cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Cerebral Palsy&#xD;
&#xD;
          2. 3 years and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent or ongoing infection&#xD;
&#xD;
          2. Clinically significant cardiovascular, lung, renal, hepatic, or endocrine disease.&#xD;
&#xD;
          3. Immunosuppression as defined by WBC &lt; 3, 000 cells/ml at baseline screening.&#xD;
&#xD;
          4. Other acute or chronic medical conditions that, in the opinion of the investigator,&#xD;
             may increase the risks associated with study participation or HB-adMSC administration.&#xD;
&#xD;
          5. Participation in other interventional research studies.&#xD;
&#xD;
          6. Unwillingness to return for follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hope.bio</url>
    <description>Hope Biosciences</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP</keyword>
  <keyword>stem cells</keyword>
  <keyword>MSCs</keyword>
  <keyword>spastic</keyword>
  <keyword>paralysis</keyword>
  <keyword>cerebral palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

